Early growth response transcription factors: Key mediators of fibrosis and novel targets for anti-fibrotic therapy
- 13 April 2011
- journal article
- review article
- Published by Elsevier BV in Matrix Biology
- Vol. 30 (4), 235-242
- https://doi.org/10.1016/j.matbio.2011.03.005
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- The Early Growth Response Gene Egr2 (Alias Krox20) Is a Novel Transcriptional Target of Transforming Growth Factor-β that Is Up-Regulated in Systemic Sclerosis and Mediates Profibrotic ResponsesThe American Journal of Pathology, 2011
- Early growth response-1 attenuates liver injury and promotes hepatoprotection after carbon tetrachloride exposure in miceJournal of Hepatology, 2010
- EGR1, EGR2, and EGR3 activate the expression of their coregulator NAB2 establishing a negative feedback loop in cells of neuroectodermal and epithelial originJournal of Cellular Biochemistry, 2010
- Fibrosis under arrestNature Medicine, 2010
- NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injuryNature Medicine, 2009
- Identification of candidate genes in scleroderma-related pulmonary arterial hypertensionTranslational Research, 2008
- Opposing regulation of T cell function by Egr‐1/NAB2 and Egr‐2/Egr‐3European Journal of Immunology, 2008
- TGF‐β signaling: A tale of two responsesJournal of Cellular Biochemistry, 2007
- Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of SnailThe EMBO Journal, 2006
- The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFβ1, PTEN, p53, and fibronectinCancer Gene Therapy, 2005